HMPL 689

Drug Profile

HMPL 689

Alternative Names: HMPL-689

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Non-Hodgkin's lymphoma

Most Recent Events

  • 29 Aug 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in China (PO) (NCT03128164; 9221910)
  • 28 Feb 2017 Hutchison Medipharma completes a phase I trial in Haematological malignancies (In volunteers) in Australia (PO) (NCT02631642)
  • 02 Aug 2016 Hutchison MediPharma plans a phase I trial for Haematological malignancies in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top